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Abstract
Dysregulated transforming growth factor beta (TGF-β) signaling is associated with a spectrum of 
osseous defects as seen in Loeys-Dietz syndrome, Marfan syndrome, and Camurati-Engelmann 
disease. Intriguingly, neurofibromatosis type 1 (NF1) patients exhibit many of these characteristic 
skeletal features, including kyphoscoliosis, osteoporosis, tibial dysplasia, and pseudarthrosis; 
however, the molecular mechanisms mediating these phenotypes remain unclear. Here, we provide 
genetic and pharmacologic evidence that hyperactive TGF-β1 signaling pivotally underpins 
osseous defects in Nf1flox/−;Col2.3Cre mice, a model which closely recapitulates the skeletal 
abnormalities found in the human disease. Compared to controls, we show that serum TGF-β1 
levels are fivefold to sixfold increased both in Nf1flox/−;Col2.3Cre mice and in a cohort of NF1 
patients. Nf1-deficient osteoblasts, the principal source of TGF-β1 in bone, overexpress TGF-β1 
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in a gene dosage–dependent fashion. Moreover, Nf1-deficient osteoblasts and osteoclasts are 
hyperresponsive to TGF-β1 stimulation, potentiating osteoclast bone resorptive activity while 
inhibiting osteoblast differentiation. These cellular phenotypes are further accompanied by p21-
Ras–dependent hyperactivation of the canonical TGF-β1–Smad pathway. Reexpression of the 
human, full-length neurofibromin guanosine triphosphatase (GTPase)-activating protein (GAP)-
related domain (NF1 GRD) in primary Nf1-deficient osteoblast progenitors, attenuated TGF-β1 
expression levels and reduced Smad phosphorylation in response to TGF-β1 stimulation. As an in 
vivo proof of principle, we demonstrate that administration of the TGF-β receptor 1 (TβRI) kinase 
inhibitor, SD-208, can rescue bone mass deficits and prevent tibial fracture nonunion in 
Nf1flox/−;Col2.3Cre mice. In sum, these data demonstrate a pivotal role for hyperactive TGF-β1 
signaling in the pathogenesis of NF1-associated osteoporosis and pseudarthrosis, thus implicating 
the TGF-β signaling pathway as a potential therapeutic target in the treatment of NF1 osseous 
defects that are refractory to current therapies.
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Introduction
Congenital pseudarthrosis, first described by James Paget in 1891, is a rare orthopedic 
condition characterized by anterolateral bowing of the tibia with tapering at the defective 
site.(1) Fractures occur early in life, and fibrous nonunion can persist even after multiple 
surgeries. Refractory cases often require amputation to restore ambulation. Fifty percent to 
ninety percent of congenital tibial pseudarthrosis cases involve mutations in the NF1 tumor 
suppressor gene,(2–5) which encodes Neurofibromin, a negative regulator of p21-Ras. 
Individuals with neurofibromatosis type 1 (NF1) have a propensity to develop a spectrum of 
osseous defects including osteoporosis,(6–11) dystrophic scoliosis,(12) increased fracture 
rates,(13,14) and pseudarthrosis,(15,16) which are associated with significant morbidity.
The molecular mechanisms responsible for low bone mass and recalcitrant fracture healing 
in NF1 patients are not clearly defined, yet deregulation of osteoclast and osteoblast 
function, the principal cellular drivers of bone resorption and bone formation, has been 
widely reported both in NF1 mouse models(17–20) as well as in osteoblasts and osteoclasts 
cultured ex vivo from human patients with the disease.(18,21,22) Transforming growth factor-
beta1 (TGF-β1) has become increasingly recognized as a critical mediator of physiological 
and pathological skeletal remodeling. Recently, Tang and colleagues(23) demonstrated the 
critical role of TGF-β1 as a master switch regulating the spatiotemporal coupling of bone 
resorption and formation. Given the considerable phenotypic overlap between the 
characteristic skeletal manifestations of NF1 with those found in other TGF-β–associated 
disorders including Loeys-Dietz syndrome,(24–27) Marfan syndrome,(28–32) and Camurati-
Engelmann disease,(33) we reasoned that dysregulated TGF-β signaling may also be integral 
to the pathogenesis of NF1 osseous defects.
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To determine whether TGF-β signaling is altered in NF1, we generated Nf1flox/−;Col2.3Cre 
mice, which recapitulate characteristic skeletal abnormalities found in NF1 patients, 
including low bone mass and tibial nonunion fracture.(34,35) Here, we report significantly 
increased TGF-β1 serum levels both in Nf1flox/−;Col2.3Cre mice and in a cohort of NF1 
patients. We further delineate a mechanism by which TGF-β1 is hypersecreted from Nf1-
deficient osteoprogenitor cells and acts to preferentially enhance Nf1+/− osteoclast bone 
resorptive activity, while inhibiting osteoblast differentiation of Nf1−/− mesenchymal stem 
cells (MSCs). By reexpressing the human, full-length neurofibromin guanosine 
triphosphatase (GTPase)-activating protein (GAP) related domain (NF1 GRD) in Nf1-
deficient osteoprogenitor cells, we demonstrate that p21-Ras–dependent hyperactivation of 
the canonical TGF-β1–Smad pathway is associated with hyperresponsiveness to TGF-β1 
signals by Nf1-deficient bone cells. Notably, treatment with a pharmacologic inhibitor of 
TGF-β receptor 1 (TβRI) kinase activity (SD-208) rescued bone mass defects and prevented 
tibial fracture nonunion in Nf1flox/−;Col2.3Cre mice. Collectively, these data implicate 
dysregulated TGF-β1 signaling as a primary factor underlying the pathogenesis of NF1-
associated osteoporosis and pseudarthrosis. Moreover, modulation of TGF-β signaling may 
serve as a potential therapeutic target in the treatment for NF1 osseous defects that are 
refractory to current modalities.
Materials and Methods
Animals
Nf1+/− mice(36) were obtained from Tyler Jacks of the Massachusetts Institute of Technology 
(Cambridge, MA, USA). Nf1flox/flox mice(37) were intercrossed with Nf1+/− and 2.3-kb α1 
(I) collagen Cre (Col2.3Cre) mice(38) to generate Nf1flox/−;Col2.3Cre mice.(34,35) For in vivo 
studies involving Nf1flox/−;Col2.3Cre(+) mice, Nf1flox/flox;Col2.3Cre(−) littermates were 
used as wild-type (WT) controls. For in vitro studies, MSCs harboring single and/or biallelic 
Nf1 inactivation were cultured from littermates with the following genotypes: WT 
(Nf1flox/flox;PeriCre(−)), Nf1+/− (Nf1flox/−;PeriCre(−)), and Nf1−/− (Nf1flox/−;PeriCre(+)). In 
this strain, the 3.9-kb fragment of the Periostin gene promoter is used to drive Cre 
expression in MSCs as reported.(35) All studies were conducted in accordance with Indiana 
University Laboratory Animal Research Center regulatory guidelines.
Serum TGF-β1 measurement and Tgfb1 gene expression
Total serum TGF-β1 levels were quantified using a mouse TGF-β1 DuoSet ELISA 
Development kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s 
protocol. TGF-β1 mRNA levels were measured by quantitative real-time PCR with SYBR 
Green reagents. Primers used for Tgfb1 were CAGTGGCTGAAC-CAAGGA (forward) and 
AGCAGTGAGCGCTGAATCG (reverse) and for Gapdh TGCACCACCAACTGCTTAG 
(forward) and GGATG-CAGGGATGATGTTC (reverse).
Osteoclast culture and dentine slice assay
Fifty thousand (5 × 104) bone marrow mononuclear cells (BMMNCs) from Nf1+/− and WT 
mice were cultured in 96-well plates in α modified essential medium (α-MEM) 
supplemented with macrophage colony-stimulating factor (M-CSF; 30ng/mL), receptor 
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activator of NF-κB ligand (RANKL; 20 ng/mL), and TGF-β1 (1 ng/mL). After 3 days, the 
medium was changed to M-CSF (30 ng/mL), RANKL (60 ng/mL), and TGF-β1 (1 ng/mL) 
for an additional 3 days of culture. Osteoclasts were fixed and stained for tartrate-resistant 
acid phosphatase (TRACP).(18) Multinucleated, TRACP-positive-staining cells containing 
more than three nuclei were scored as mature osteoclasts. The bone resorptive capacity of 
osteoclasts was characterized by seeding 1 × 105 BMMNCs onto dentine slices. Following 7 
days culture in the presence of M-CSF and RANKL at 37°C, 5% CO2, dentine slices were 
rinsed with PBS and immersed overnight in 1 M ammonium hydroxide. After staining with 
a 1% crystal violet solution, the number and area of resorptive “pits” were quantified using 
NIH Image J Software on low-power fields (x100 magnification).
MSC culture and osteoblast differentiation
BMMNCs were cultured in MesenCult media (Stem Cell Technologies Inc., CA, USA) at 
37°C, 5% CO2.(19) MSCs of identical passage number (between passages 5 and 10) were 
used for experiments. For osteoblast differentiation, 5 × 104 MSCs were cultured for 7 days 
in 12-well plates using MesenCult media supplemented with 10−8 M dexamethasone, 5 
mg/mL ascorbic acid 2-phosphate, and 10mM β-glycerophosphate. Alkaline phosphatase 
(ALP) staining was performed to assess osteoblast differentiation.(19)
Retroviral restoration of NF1 GRD
MSCs were transduced with recombinant retrovirus constructs to achieve expression of the 
full-length NF1 GRD under the transcriptional control of the murine stem cell virus 
promoter (MSCV) as described.(19,39) Puromycin (4 µg/mL) was used for cell selection.
Western blot analysis and gelatin zymography
Following stimulation with TGF-β1 and/or TβRI kinase inhibitor (SD-208), cells were lysed 
in a radioimmunoprecipitation assay (RIPA) lysis buffer containing protease and 
phosphatase inhibitors. Isolated proteins were fractionated using NuPAGE 4–12% Bis-Tris 
Gels (Invitrogen) and electrotransferred to polyvinylidene fluoride (PVDF) membranes. 
Callus proteins were harvested 14 days after tibial fracture using a mortar and pestle to grind 
the callus in proteolysis buffer. Immunoblots were performed using antibodies specific to p-
Smad2 (Cell Signaling), total Smad2 (Cell Signaling), active TGF-β1 (R&D Systems), latent 
latency-associated peptide (LAP)-TGF-β1 (R&D Systems), β-actin (Sigma), and GAPDH 
(Cell Signaling). Gelatinolytic activities of murine myeloid cell-conditioned media and 
human serum samples were assessed using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) under nonreducing conditions.(40) Renaturation of the 
electrophoresed enzymes was achieved by incubation in a 0.15 M NaCl, 5 mM CaCl2,0.05% 
NaN3,50 mM Tris-HCl, pH 7.5 buffer at 37°C for 48 hours. Zones of lytic activity were 
revealed by Coomassie blue staining.
Smad dual-luciferase reporter assays
Osteoprogenitors were transfected with Smad reporter, negative, and positive control dual-
luciferase constructs (Cignal Reporter Assay; Qiagen).(41) Transfected cells were stimulated 
with recombinant active TGF-β1 (1 ng/mL) or latent LAP-TGF-β1 (100 ng/mL) for 18 
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hours. Firefly and Renilla luciferase activities were measured on a 96-well microtiter plate 
luminometer (Thermo Labsystems) with LAR II and Stop&Glo reagents (Promega Dual 
Luciferase Assay Kit).
Tibial fracture and TβRI inhibitor treatment
Open tibial fractures were induced by a three-point method in 12-week-old 
Nf1flox/−;Col2.3Cre mice under ketamine anesthesia as described.(35,42) Proper fracture 
position between the middle to distal 1/3 of the tibia below the fibular junction was 
confirmed by X-ray (pixRay-100; Bioptics, Phoenix, AZ, USA). Weekly radiography was 
performed to monitor fracture healing until the experimental endpoint of 4 weeks. The mice 
were treated with the TβRI kinase inhibitor, SD-208 (60 mg/kg/day), or vehicle control (1% 
methylcellulose in sterile water) by daily gavage.
Peripheral dual-energy X-ray absorptiometry and micro–computed tomography
Bone mineral density (BMD) was measured by peripheral dual-energy X-ray absorptiometry 
(pDXA) using a PIXImus mouse densitometer (GE Lunar II; Faxitron Corp., Wheeling, IL, 
USA) (n = 15/group). The region of interest (ROI) was defined as the distal femur just 
proximal to the growth plate (12×12 pixels). Formalin-fixed femurs were placed in the 
gantry of a micro–computed tomography (µCT) scanner (VivaCT 40; Scanco Medical AG, 
Bassersdorf, Switzerland). Images were acquired at a voxel size of 10.5 µm. The voxel of 
interest (VOI) comprised 100 transverse CT slices beginning 250 µm away from the femoral 
growth plate and extending proximally. Fractional bone volume (BV/TV) and architectural 
properties of trabecular reconstructions, including trabecular thickness (Tb.Th, mm), 
trabecular number (Tb.N, per mm), trabecular spacing (Tb.Sp, mm), and connectivity 
density (Conn.D, per mm3) were calculated using standard algorithms.
Quantitative histomorphometry and immunohistochemistry
Tissues were fixed in 10% formalin for 48 hours, demineralized for 2 weeks in 10% EDTA, 
and embedded in paraffin for histological sectioning. BV/TV of the secondary spongiosa and 
osteoblast number (N.Ob/BS) normalized to the bone surface were quantified on 
hematoxylin and eosin (H&E)-stained sections of the distal femur at ×200 magnification 
using BIOQUANT OSTEO v11.2 software (BIOQUANT Image Analysis Inc., Nashville, 
TN, USA). Osteoclast number normalized to the bone surface (N.Oc/BS) was quantified on 
TRACP-stained sections at ×200 magnification. For immunohistochemical staining, sections 
were incubated in DeCal Retrieval Solution (Biogenex Laboratories, San Ramon, CA, USA) 
for 30 minutes at room temperature. Primary antibody to p-Smad2 (Cell Signaling; diluted 
1:100) was applied overnight at 4°C. The Vectastain ABC kit containing biotinylated 
secondary antibody (diluted 1:2000) and 3,3’-diaminobenzidine (DAB) substrate kit (Vector 
Laboratories, Burlingame, CA, USA) were used for detection. Quantification of p-Smad2 
staining in fracture calluses was performed with Aperio ImageScope v11.1.2.760 software 
using the Positive Pixel Count v9 algorithm under default settings.
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Statistical analysis
Differences between experimental groups were determined by Student’s t test or analysis of 
variance (ANOVA), followed by Newman-Keuls multiple comparison tests where 
appropriate. Values of p < 0.05 were considered significant.
Results
Nf1 regulates TGF-β1 expression in MSCs
In human disease, alterations in TGF-β signaling occur via several mechanisms, including 
aberrant ligand expression/activation, receptor mutations, and dysregulation of downstream 
effector pathways. We examined the serum TGF-β1 levels in Nf1flox/−;Col2.3Cre mice, 
which closely recapitulate a spectrum of osseous manifestations seen in NF1 patients. 
Strikingly, we found that the serum level of total TGF-β1 in Nf1flox/−;Col2.3Cre mice was 
elevated fivefold to sixfold as compared to WT controls (Fig. 1A). To identify the cell type 
responsible for TGF-β1 overproduction, we examined TGF-β1 expression at the mRNA and 
protein levels from WT, Nf1+/−, and Nf1−/− osteoblast progenitors (MSCs), as this lineage is 
the principal source of TGF-β1 in bone.(43) Nf1+/− and Nf1−/− MSCs, as compared with WT 
cells, expressed significantly more TGF-β1 mRNA (Fig. 1B) and protein (Fig. 1C). Further 
corroborating neurofibromin’s function as a negative regulator of TGF-β1 expression, we 
observed significantly increased serum TGF-β1 levels in human NF1 patients as compared 
to healthy controls (Fig. 1D). Collectively, these data imply that single or biallelic Nf1 
inactivation leads to pathological TGF-β1 overproduction in a gene dosage–dependent 
fashion.
Loss of Nf1 leads to p21-Ras–dependent TGF-β1 overexpression and activation of the 
Smad pathway in MSCs, inhibiting osteoblast differentiation
Canonical TGF-β signaling involves the phosphorylation of Smad proteins by TβRI.(44) To 
examine the role of Nf1 in regulating this pathway, we compared TGF-β1–induced 
activation of Smad2 in WT, Nf1+/−, and Nf1−/− MSCs. We observed an increase in TGF-β1–
induced Smad2 phosphorylation in Nf1−/− osteoprogenitors versus WT controls (Fig. 2A), 
whereas the total protein expression of Smad2 (Fig. 2A), TβRI and TβRII (Supplemental 
Fig. 1A) remained constant. We further postulate that increased basal levels of p-Smad2 in 
Nf1+/− and Nf1−/− MSCs, as compared to WT cultures, are likely indicative of the autocrine 
feedback effect of TGF-β1 hypersecreted by Nf1-deficient MSCs as characterized in Fig. 1.
To assess the implications of increased TGF-β1 biochemical activity on osteoblastogenesis, 
WT and Nf1−/− MSCs were cultured in osteogenic differentiation medium supplemented 
with TGF-β1. Expression of the osteoblast marker ALP, which is impaired at the baseline 
level in Nf1−/− osteoblasts, was further reduced by 87% in Nf1−/− cells as compared to just 
53% in WT osteoblast cultures stimulated with TGF-β1 (Fig. 2B). Application of SD-208, 
an inhibitor of TβRI activity, was effective in attenuating Smad phosphorylation to basal 
levels (Supplemental Fig. 1B) and in rescuing ALP expression (Supplemental Fig. 1C). 
Collectively, these results corroborate neurofibromin’s role as a suppressor of canonical 
TGF-β1 signaling in osteoblasts, whereby haploinsufficient or nullizygous Nf1 gene 
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ablation enhances TGF-β1–dependent Smad phosphorylation and exacerbates intrinsic 
deficits in terminal osteoblast differentiation —a critical component of bone anabolism.
To further demonstrate that reductions in ALP activity induced by TGF-β1 in Nf1-deficient 
MSCs are reflective of an osteoblast differentiation defect, as opposed to other mechanisms 
such as an impaired proliferative response or lineage selection, we performed additional 
experiments to test these alternative hypotheses. Here we show that TGF-β1 significantly 
increases the proliferation of WT and Nf1−/− MSCs (Supplemental Fig. 1D), whereas 
proliferative responses to TGF-β1 were suppressed to below even basal levels following 
TβRI kinase inhibition (SD-208). These data are consistent with a number of studies 
illustrating the mitogenic effects of TGF-β1 on osteoprogenitors, as summarized by Janssens 
and colleagues.(43) To exclude lineage selection as a potential factor mediating the 
differential responses of WT and Nf1−/− MSCs to TGF-β1 stimulation, we compared the 
expression levels of several MSC cell-surface markers in WT versus Nf1−/− MSCs. Flow 
cytometric analysis revealed no differences in the expression pattern of CD105 and CD29 
surface antigens when comparing WT and Nf1−/− MSCs (Supplemental Fig. 1E). Taken 
together, these data suggest that TGF-β1–mediated reductions in ALP activity in WT and 
Nf1-deficient osteoprogenitor cells are primarily due to osteoblast differentiation defects in 
response to TGF-β1, rather than alterations in lineage selection or an impaired proliferative 
response of MSCs/osteoblast progenitor cells following TGF-β1 stimulation.
Given neurofibromin’s apparent function as a negative regulator of TGF-β1 expression and 
signaling, we therefore reasoned that p21-Ras hyperactivity may be associated with 
increased Tgfb1 gene expression and Smad-dependent signaling in the absence of Nf1. To 
test this hypothesis, we transduced Nf1-deficient MSCs with a recombinant retrovirus 
encoding the full-length NF1 GRD and a selectable marker, pac, which confers resistance to 
puromycin.(19) As compared to Nf1−/− MSCs expressing MSCV-pac alone, reconstitution of 
the full length of NF1 GRD in Nf1-deficient MSCs attenuated the expression of TGF-β1 
mRNA transcripts by nearly 50% (Fig. 2C) and suppressed Smad phosphorylation (Fig. 2D) 
following TGF-β1 stimulation. When we repeated these studies in WT MSCs, no significant 
differences in Tgfb1 gene expression (Supplemental Fig. 2A) or Smad-dependent signaling 
(Supplemental Fig. 2B) were observed when comparing cells transduced with either the 
MSCV-pac or MSCV-NF1 GRD-pac constructs. Unlike in Nf1−/− MSCs in which Ras 
activation proceeds unabated, Ras activity in WT cells is tightly regulated by endogenous 
full-length neurofibromin. This might explain the minimal effect on TGF-β1 expression and 
Smad signaling when NF1 GRD is overexpressed in WT cells. The reduction in TGF-β1 
expression and signaling specifically in Nf1-deficient MSCs is consistent with the 
normalization of Ras GTP activity following reconstitution with functional NF1 GRD, as we 
have reported.(19) Collectively, these data suggest that functional inactivation of 
neurofibromin and p21-Ras hyperactivity are associated with dysregulation of TGF-β1 
expression and Smad-dependent signaling in Nf1-deficient MSCs.
Hyperactive TGF-β1 signaling potentiates Nf1+/− osteoclast catabolic activity
Given that TGF-β1 has a pivotal impact on cellular functions of both osteoblasts and 
osteoclasts in bone development, we next examined the effects of TGF-β1 on aberrant bone 
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catabolic activity by Nf1 haploinsufficient osteoclasts. BMMNCs cultured from Nf1+/− mice 
demonstrated a significantly increased capacity to form TRACP-positive staining, 
multinucleated osteoclasts following treatment with TGF-β1 as compared to WT controls 
(Fig. 3A). Application of TβRI kinase inhibitor (SD-208) attenuated osteoclast formation in 
a dose-dependent fashion, with an observable effect beginning at 100 nM in the Nf1+/− 
cultures as compared to 500 nM in the WT cells (Fig. 3B). Actin ring formation, a 
prerequisite for osteoclast bone resorption, was also increased in Nf1+/− osteoclasts cultured 
in the presence of TGF-β1, and suppressed by escalating concentrations of SD-208 
(Supplemental Fig. 3A). To directly assess the effects of TGF-β1 on osteoclast function, WT 
and Nf1+/− osteoclasts were cultured on dentine slices in the presence of TGF-β1. Nf1+/− 
osteoclasts generated markedly increased numbers of resorptive “pits” following treatment 
with TGF-β1 as compared to WT controls (Fig. 3C), suggesting that TGF-β1 can 
preferentially activate osteoclast bone resorptive activity in the context of Nf1 
haploinsufficiency. TβRI kinase inhibition attenuated “pit” formation to basal levels in both 
WT and Nf1+/− osteoclast cultures. We further show that Nf1+/− osteoclast 
hyperresponsiveness to TGF-β1 is correlated with increased biochemical activation of the 
TGF-β1/Smad pathway. Increased levels of phosphorylated Smad2 were detected in Nf1+/− 
osteoclasts stimulated with TGF-β1, whereas total levels of Smad2 protein were equivalent 
between the two genotypes (Fig. 3D). Osteoclasts cultured from the peripheral blood of a 
human NF1 patient and an age/sex-matched healthy control exhibited a similar phenotype 
when treated with TGF-β1 (Supplemental Fig. 3B). In sum, these data indicate that 
neurofibromin functions to negatively regulate Smad-dependent TGF-β1 signaling in 
osteoclasts, whereby Nf1 haploinsufficiency promotes excess osteoclast bone lytic activity 
via hypersensitivity to TGF-β1 stimulation.
Although Nf1+/− mice do not exhibit spontaneous bone mass deficits, we have previously 
demonstrated that they exhibit significantly increased osteolytic activity (twofold increased 
bone loss as compared to WT controls) in response to ovariectomy (OVX) induced pro-
resorptive stress.(18) To further assess the functional contribution of hyperactive TGF-β1 
signaling toward accelerated osteolytic activity in ovariectomized Nf1+/− mice, we tested 
whether TβRI kinase inhibition could abrogate excess osteoclast catabolic activity in Nf1+/− 
OVX mice. WT and Nf1+/− mice underwent either OVX or sham surgery followed by 6 
weeks treatment with SD-208, 60 mg/kg/d, versus vehicle control (1% methylcellulose in 
sterile water). Here, we show that pharmacologic TβRI kinase inhibition effectively 
preserved femoral BMD (Supplemental Fig. 4A) and trabecular BV/TV (Supplemental Fig. 
4B,C) in OVX mice as compared to the vehicle-treated cohort, in which bone loss was 
approximately twofold greater in the Nf1+/− OVX mice versus WT OVX controls. 
Trabecular microarchitecture parameters (Supplemental Fig. 4D–G) including Conn.D, 
Tb.N, Tb.Sp, and structure model index (SMI) were also restored to the level of sham-
operated controls following SD-208 administration in OVX mice.
Histological methods corroborated these results (Supplemental Fig. 4H) and provided 
insights regarding the cellular mechanism of the observed phenotype. Osteoclast numbers, 
which were markedly increased in vehicle-treated Nf1+/− OVX mice, returned to baseline 
levels following SD-208 treatment (Supplemental Fig. 4I). Serum levels of the C-terminal 
cross-linking telopeptide of type I collagen (CTX), an established biomarker of osteolytic 
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activity, were significantly increased in vehicle-treated Nf1+/− OVX mice, but normalized 
after SD-208 treatment (Supplemental Fig. 4J). Overall, the accentuated response of Nf1+/− 
OVX mice to TβRI kinase inhibition underscores the pivotal role of TGF-β in potentiating 
osteoclast bone erosive activity in the context of Nf1 haploinsufficiency.
TβRI inhibition rescues bone defects in Nf1flox/−;Col2.3Cre mice
Recently, our laboratory established that Nf1flox/−;Col2.3Cre mice spontaneously 
recapitulate characteristic skeletal manifestations found in NF1 patients, including low bone 
mass and tibial nonunion fracture.(34,35) In this model, we demonstrate that the cooperative 
interaction between conditional Nf1−/− osteoblasts and Nf1+/− hematopoietic cells, including 
osteoclasts, is integral to the pathogenesis of the bone defects.(35) Recent clinical data 
support this hypothesis, confirming that at least a subset of NF1 pseudarthrosis patients 
exhibit biallelic NF1 inactivation in tissue microdissected from the lesion site.(45,46) Based 
on these findings, we reasoned that a cycle of uncoupled bone remodeling perpetuated by 
TGF-β1 overproduction and hypersensitivity may pivotally underlie the pathogenesis of 
bone defects observed in the Nf1flox/−;Col2.3Cre murine model. Therefore, we tested 
whether pharmacologic inhibition of TβRI kinase activity could rescue characteristic NF1-
associated bone defects such as osteoporosis and tibial fracture nonunion observed in 
Nf1flox/−;Col2.3Cre mice.(34,35)
Cohorts of 3-month-old to 4-month-old Nf1flox/−;Col2.3Cre mice received daily treatment 
with the TβRI kinase inhibitor, SD-208 (60 mg/kg/d) or the vehicle control (1% 
methylcellulose in sterile water) for 4 weeks. BMD measurements were acquired both 
pretreatment and posttreatment to track the percent change in BMD during the treatment 
period (Fig. 4A). µCT (Fig. 4B) and histological sections (Fig. 4C; Supplemental Fig. 5A) of 
the excised bones illustrate the low bone mass phenotype of vehicle treated 
Nf1flox/−;Col2.3Cre mice as compared to WT controls. In contrast, dramatic increases in 
BMD and trabecular BV/TV (Fig. 4A) were observed in Nf1flox/−;Col2.3Cre mice treated 
with SD-208. Although WT mice began treatment with nearly twice the bone mass of 
Nf1flox/−;Col2.3Cre mice prior to therapy, we observed no significant differences in bone 
mass (Fig. 4A) or trabecular architecture parameters (Supplemental Fig. 5B–D) between WT 
and Nf1flox/−;Col2.3Cre mice following SD-208 treatment, indicating that pharmacologic 
TGF-β inhibition completely rescued bone mass defects in the Nf1flox/−;Col2.3Cre mice. On 
the cellular level, osteoblast numbers, which were diminished in vehicle-treated 
Nf1flox/−;Col2.3Cre mice, were significantly increased following SD-208 treatment (Fig. 
4D). By contrast, osteoclast numbers, which were elevated in vehicle-treated 
Nf1flox/−;Col2.3Cre mice, were attenuated to WT levels following SD-208 treatment 
(Supplemental Fig. 6A,B). In summary, the striking response of Nf1flox/−;Col2.3Cre mice to 
TβRI kinase inhibition—even as compared to WT animals that also received SD-208 
treatment—substantiates the pivotal role of aberrant TGF-β signaling in the pathogenesis of 
NF1-associated osteopenia and osteoporosis in the murine system.
Nonunion fracture of long bones, particularly the tibia, carries significant morbidity in NF1 
patients. This clinical feature is also recapitulated in Nf1flox/−;Col2.3Cre mice.(35) 
Immunohistochemical analysis of Nf1flox/−;Col2.3Cre mice with tibial fracture nonunion 
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revealed approximately threefold-increased levels of pSmad-2 within the fracture site as 
compared to WT controls (Fig. 5A). If aberrant TGF-β signaling indeed underlies 
recalcitrant bone healing in NF1, we reasoned that pharmacologic TβRI blockade might 
prevent tibial fracture nonunion in Nf1flox/−;Col2.3Cre mice. To test this hypothesis, cohorts 
of Nf1flox/−;Col2.3Cre mice were treated with SD-208 (60 mg/kg/d) or vehicle control for 6 
weeks following tibial fracture. Compared to healthy WT mice, which exhibit robust callus 
formation, radiographic monitoring (Supplemental Fig. 7) demonstrated persistent fracture 
nonunion in Nf1flox/−;Col2.3Cre mice treated with the vehicle control, with minimal or 
complete absence of callus formation at the fracture site. Administration of SD-208 in 
Nf1flox/−;Col2.3Cre mice substantially enhanced callus formation as compared to those 
receiving vehicle treatment. µCT evaluation of callus structural integrity further revealed a 
significant increase in callus BV/TV in Nf1flox/−;Col2.3Cre mice undergoing SD-208 
treatment (Fig. 5B), suggesting that pharmacologic TβRI inhibition improved bone 
formation within the fracture site. Histological sectioning (Fig. 5C) revealed fibrous tissue 
and an increased presence of TRACP-positive–staining osteoclasts within the fracture site of 
Nf1flox/−;Col2.3Cre mice receiving vehicle treatment. SD-208 treatment significantly 
reduced osteoclast numbers and p-Smad2 levels (Fig. 5D) within the fracture callus. 
Collectively, these results provide the first direct evidence that pharmacologic TGF-β 
blockade is an effective therapeutic strategy to augment bone healing in a mouse model of 
NF1 tibial pseudarthrosis.
Hypersecretion of matrix metalloproteinase-2 or matrix metalloproteinase-9 potentiates 
latent TGF-β1 activation
In order for TGF-β1 to bind to its receptors and exert its biological effects, it must be 
cleaved from its LAP. When we measured the levels of latent, LAP-bound TGF-β1 versus 
active TGF-β1 in Nf1flox/−;Col2.3Cre mice with tibial fracture nonunion, we observed a 
dramatic increase in the ratio of active-to-latent TGF-β1 within the facture site as compared 
to WT controls (Fig. 6A), implying that accelerated conversion of latent TGF-β1 to the 
active form may play an important role in upregulating the bioavailability of active TGF-β1. 
Cleavage of the TGF-β LAP is known to occur through both acid and enzymatic 
mechanisms.(47) Among these, matrix metalloproteinase 2 (MMP-2) and MPP-9 have been 
shown to mediate the proteolysis of LAP and play an important role in bone remodeling and 
fracture healing in animal models.(48–51) We next measured the levels of active MMPs in the 
conditioned medium of Nf1 haploinsufficient myeloid cells by gelatin zymography. In 
particular, the gelatinase activity of MMP-2/9 was significantly enhanced in Nf1+/− myeloid 
cell conditioned medium versus WT controls (Fig. 6B; Supplemental Fig. 8A). We similarly 
observed a 5.4-fold increase in MMP-2 activity in the serum of a NF1 patient as compared 
to a matched, healthy control (Supplemental Fig. 8B,C). To demonstrate that only the active 
form of TGF-β1 can promote hyperactivation of the canonical Smad pathway, we 
transfected Nf1 nullizygous osteoprogenitors with a Smad luciferase reporter construct and 
subsequently stimulated the transfected cells with either recombinant, active TGF-β1 (1 
ng/mL) or 100 times the dose of latent, LAP-bound TGF-β1 (100 ng/mL). Expectedly, Smad 
luciferase reporter activity was nearly 75% greater in Nf1−/− osteoprogenitors stimulated 
with recombinant active TGF-β1 as compared to WT controls, but not in cells stimulated 
with LAP-TGF-β1 (Fig. 6C).
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Discussion
The precise role of TGF-β1 in regulating skeletal homeostasis has been historically difficult 
to define. Observations that exogenously administered TGF-β1 can stimulate bone 
formation(14,40,52) implicate TGF-β1 as an anabolic factor in bone metabolism. Conversely, 
recent genetic(53,54) and pharmacologic(55,56) data demonstrate that attenuation of 
endogenous TGF-β1 signaling may in fact augment bone mass and quality by 
simultaneously enhancing osteoblast differentiation while inhibiting osteoclast recruitment. 
Here, we demonstrate that hyperactive TGF-β1 signaling plays a pivotal role in the 
pathogenesis of fracture nonunion and osteoporosis in a mouse model of the common 
autosomal dominant genetic disorder, NF1.
Previous genetic studies suggest that either overabundance or deficiency of TGF-β1 can lead 
to poor bone quality. TGF-β1 knockout mice exhibit reduced BMD, cortical thickness, and 
fracture toughness.(57,58) By contrast, mice overexpressing TGF-β in osteoblasts show gene 
dosage–dependent reductions in bone mineral concentration, elastic modulus, and hardness.
(54)
 Tang and colleagues(23) recently established a murine model that carries a Camurati-
Engelmann disease (CED)-derived mutant TGF-β1. These TGF-β1 mutant mice 
demonstrate high levels of active TGF-β1 and exhibit progressive diaphyseal dysplasia 
similar to that seen in patients with CED.(23) Similarly, individuals with Loeys-Dietz and 
Marfan syndrome, both of which involve altered TGF-β signaling, exhibit characteristic 
skeletal manifestations including osteopenia,(25,26,29–31) scoliosis,(24,32,59) and an increased 
incidence of pseudarthrosis following orthopedic instrumentation.(60,61) It has been 
hypothesized that chronically elevated serum TGF-β levels may also underlie bone loss in 
states such as hepatic and/or renal osteodystrophy.(62)
In the present study, we show that Nf1flox/−;Col2.3Cre mice, which recapitulate multiple 
NF1-associated skeletal abnormalities including osteoporosis and nonunion fracture healing,
(34,35)
 exhibit fivefold to sixfold elevated serum TGF-β1 levels as compared to WT controls. 
Serum TGF-β1 levels were similarly increased in a cohort of human NF1 patients, as shown 
herein. Consistent with these data, we previously reported that Nf1 haploinsufficient mast 
cells hypersecrete TGF-β, perpetuating excessive fibroblast proliferation and collagen 
synthesis within the neurofibroma microenvironment.(63) More recently, Wang and 
colleagues(64) noted increased TGF-β mRNA levels in the fracture calluses of mice 
harboring conditional Nf1 nullizygous osteoblasts.
Beyond merely overexpressing TGF-β1, Nf1 mutant osteoblasts and osteoclasts 
pathologically differentiated and excessively resorbed bone in response to TGF-β1. These 
cellular dysfunctions were associated with increased activation of the canonical Smad 
pathway. Reexpression of the human, full-length NF1 GRD in Nf1-deficient 
osteoprogenitors attenuated TGF-β1 expression levels and inhibited Smad phosphorylation 
in response to TGF-β1 stimulation, thus validating that TGF-β1–mediated biochemical gain-
in-functions within neurofibromin-deficient bone cells occur in a p21-Ras–dependent 
fashion.
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The elevated ratio of active-to-latent TGF-β1 in Nf1flox/−;Col2.3Cre mice with tibial fracture 
nonunion further suggests that accelerated cleavage of the TGF-β1 LAP may also play an 
important role in upregulating the bioavailability of active TGF-β1 within the bone matrix. 
Several factors are known to activate latent TGF-β, including integrins,(65) 
thrombospondin-1,(66) and MMP-2/9.(67) In the present study, we found increased levels of 
active MMP-2 and MMP-9 in both the conditioned media of Nf1 haploinsufficient myeloid 
cells and the serum of a human NF1 patient as compared to controls. Intriguingly, genetic 
ablation of MMP-2 and MMP-9 has been shown to alter bone remodeling(51) and fracture 
repair.(48,50) Moreover, patient-derived hypertrophic nonunion fracture tissue was also found 
to overexpress MMP-7 and MMP-12 in a recent clinical study.(49) Collectively, these 
findings suggest the need for further investigation regarding the relationship between MMPs 
and TGF-β1 activation in normal and Nf1-deficient bone healing.
Recent clinical studies(21,22,45) and animal models(18,34,35,64,68–70) suggest that cooperative 
interactions between local Nf1-nullizygous osteoprogenitors and Nf1 haploinsufficient 
osteoclasts of the bone marrow play a critical role in modulating the disease process. By 
restoring the balance of coordinated osteoclast and osteoblast activity in NF1, attenuating 
TGF-β signaling may hold advantages over traditional monotherapies such as 
bisphosphonates, parathyroid hormone (PTH), bone morphogenic protein (BMP), or vitamin 
D, which selectively target either the osteoclast or the osteoblast alone. Furthermore, Heervä 
and colleagues(71) recently demonstrated that osteoclasts derived from human NF1 patients 
were insensitive to bisphosphonate treatment versus healthy controls, reinforcing the need to 
develop novel targeted therapies designed specifically for the NF1 patient population. Here, 
we show that suppression of hyperactive TGF-β signaling can normalize the dysregulated 
functioning of Nf1-deficient osteoblasts and osteoclasts, thereby restoring bone mass and 
preventing tibial fracture nonunion in Nf1flox/−;Col2.3Cre mice. These results underscore the 
need for next-generation, highly selective TGF-β pharmacological inhibitors that could 
effectively treat the current therapy-resistant bone pathologies of NF1 patients.
In summary, this study provides direct preclinical evidence that dysregulated TGF-β 
signaling underlies osteoporosis and nonunion fracture in patients with NF1. These in vivo 
data also verify the regulatory role of TGF-β signaling in osteoclast and osteoblast biology
—a complex topic that has been historically difficult to assess as a result of biphasic and 
dose-dependent effects of TGF-β on bone cells in in vitro culture. The marked response of 
Nf1flox/−;Col2.3Cre mice to pharmacologic TGF-β inhibition—even as compared to WT 
controls also undergoing treatment—underscores the critical importance of the TGF-β 
pathway in the genesis of NF1-associated bone defects and as a target for therapeutic 
intervention. Taken together, these data suggest a proposed model (Fig. 6D) in which genetic 
inactivation of Nf1 in osteoprogenitor cells results in increased TGF-β1 synthesis and 
systemically elevated TGF-β1 levels. We further postulate that excess quantities of latent, 
LAP-bound TGF-β1 sequestered within the bone matrix may be liberated at an accelerated 
rate by hyperresorptive Nf1+/− osteoclasts and subsequently activated by increased levels of 
MMP-2 and MMP-9 secreted by Nf1 haploinsufficient myeloid cells. In turn, we propose 
that active TGF-β1 feeds back to perpetuate a cycle of accelerated osteolytic activity while 
simultaneously suppressing a compensatory osteoblast anabolic response. At the molecular 
level, hypersensitivity of Nf1-deficient bone cells to TGF-β1 stimulation was associated 
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with increased biochemical activation of the Smad pathway. Further supporting the 
paradigm that aberrant TGF-β1 signaling pivotally underpins NF1-associated osseous 
defects, we demonstrate that disruption of this pathological paracrine circuitry via 
pharmacologic inhibition of TβRI kinase activity (SD-208) can rescue bone mass deficits 
and prevent tibial fracture nonunion in Nf1flox/−;Col2.3Cre mice. Given that current 
treatment outcomes for pseudarthrosis in NF1 remain poor, the potential application of 
pharmacologic TGF-β inhibitors to augment bone union warrants further preclinical and 
early phase clinical trials.
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Fig. 1. 
Nf1 gene dose regulates TGF-β1 production by osteoblasts. (A) Serum TGF-β1 levels were 
measured by ELISA in WT and Nf1flox/−;Col2.3Cre mice. n = 4 mice per group. ****p < 
0.0001. (B) TGF-β1 mRNA expression in WT, Nf1+/−, Nf1−/− osteoblast progenitors was 
examined by quantitative PCR. n = 3 technical replicates. The experiment was repeated 
twice with similar results using independent cell lines. **p < 0.01, ****p < 0.0001. (C) 
Protein extracts were examined by ELISA to determine TGF-β1 protein expression. n = 3 
technical replicates. The assay was repeated twice with similar results using independent cell 
lines. **p < 0.01, ****p < 0.0001. (D) Serum TGF-β1 levels were measured by ELISA in 
human NF1 patients and healthy controls. n = 7 samples per group. **p < 0.01.
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Fig. 2. 
Nf1-deficient MSCs exhibit hyperactivation of the Smad pathway and impaired osteoblast 
differentiation in response to TGF-β1. (A) p-Smad2, Smad2, and GAPDH levels were 
detected by Western blot in MSCs stimulated with TGF-β1. The quantitative fold change in 
p-Smad2 was determined relative to the loading control, as shown in the bar graph. The 
experiment was repeated on three independent occasions with similar results. (B) MSCs 
were cultured in osteogenic differentiation medium supplemented with TGF-β1. 
Representative photomicrographs (top panel) show alkaline phosphatase (ALP)-positive 
Rhodes et al. Page 19
J Bone Miner Res. Author manuscript; available in PMC 2019 October 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
osteoblasts (magnification × 200). ALP expression was quantified and normalized to the WT 
control as shown (bottom panel). n = 3 technical replicates. The assay was repeated twice 
with similar results using independent cell lines. **p < 0.01, ***p < 0.001. (C) TGF-β1 
mRNA expression was measured in Nf1−/− MSCs following retroviral transduction with 
control vector (MSCV-pac) versus the functional, full-length NF1 GRD construct. n = 3 
technical replicates. The experiment was repeated on three independent occasions with 
similar results. *p < 0.05. (D) p-Smad2, Smad2, and GAPDH levels were detected by 
Western blot in MSCs stimulated with TGF-β1 following transduction with either MSCV-
pac or MSCV-NF1 GRD retroviral vectors. The quantitative fold change in p-Smad2 was 
determined relative to the level of total Smad2 protein, as shown in the bar graph.
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Fig. 3. 
TGF-β1 potentiates Nf1 haploinsufficient osteoclast gain-in-functions, which are 
accompanied by increased activation of the Smad pathway. (A) Osteoclast formation from 
BMMNCs was induced by M-CSF and RANKL, in the presence or absence of TGF-β1 (1 
ng/mL). Representative photomicrographs show multinucleated osteoclasts (magnification 
×200) following TRACP staining. Bar graphs represent the mean number of nuclei per 
osteoclast and the area of TRACP-positive, multinucleated osteoclasts per high power field 
(HPF), quantified using ImageJ software. n = 4 biological replicates. The experiment was 
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repeated three times with similar results. *p < 0.05, **p < 0.001. (B) Osteoclast formation 
following TGF-β1 stimulation and increasing doses of SD-208. n = 3 biological replicates. 
*p < 0.05, **p < 0.01 comparing Nf1+/− versus WT. (C) Osteoclast bone resorption on 
dentine slices. Representative photomicrographs show resorptive “pits” (magnification × 
100). “Pit” area was quantified as shown by the bar graph above. n = 3 biological replicates. 
***p < 0.0001. (D) Phosphorylated Smad2 (p-Smad2), total Smad2, and β-actin were 
measured by Western blot in preosteoclasts stimulated with TGF-β1 (1 ng/mL) in the 
presence or absence of SD-208 (100 nM). The bar graph shows the fold change in p-Smad2 
relative to the loading control. The assay was repeated on two independent occasions with 
similar results.
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Fig. 4. 
TβRI inhibition restores bone mass in Nf1flox/−;Col2.3Cre mice. (A) (Top) The percentage 
change in BMD of the distal femur was determined by pDXA before and after 4 weeks of 
treatment with vehicle or SD-208 (60mg/kg/d). n = 7 to 12 mice per group. *p < 0.05, **p < 
0.01, ***p < 0.001. (Bottom) Trabecular bone volume fraction (BV/TV) was quantified by 
µCT. n = 7 to 12 mice per group. *p < 0.05, **p < 0.01. (B) Representative µCT 
reconstructed femora in longitudinal (top) and transverse (bottom) cross-sections after 4 
weeks treatment with vehicle or SD-208 treatment. (C) Representative longitudinal sections 
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of H&E stained femora, ×25 magnification. (D) The osteoblast number per millimeter of 
bone surface was quantified by manually counting osteoblasts on H&E-stained sections 
(×200 magnification). n = 7 to 12 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 5. 
TβRI inhibition prevents tibial fracture nonunion in Nf1flox/−;Col2.3Cre mice. (A) 
Immunohistochemical staining for p-Smad2 in fracture calluses of WT and 
Nf1flox/−;Col2.3Cre mice. The p-Smad2–positive staining area was normalized to the tissue 
area and compared between genotypes. n = 6 mice per group. **p < 0.01. (B) (Top) 
Representative µCT reconstructed whole callus and longitudinal cross-sections from 
Nf1flox/−;Col2.3Cre mice treated with either vehicle or SD-208 for 4 weeks following tibial 
fracture. (Bottom) Callus bone volume fraction (BV/TV) was quantified by µCT as shown in 
the bar graph. n = 6 to 8 mice per group. *p < 0.05. (C) Representative tibial fractures in 
longitudinal cross-sections stained with H&E (x25 magnification), trichrome (x100 
magnification), and TRACP (x50 magnification). (D) (Left) The fold change in osteoclast 
number (Oc.N) per millimeter of bone surface (BS) in SD-208–treated Nf1flox/−;Col2.3Cre 
mice relative to the vehicle-treated cohort was determined by manually counting 
multinucleated TRACP-positive cells. n = 6 mice per group. *p < 0.05. (Right) Tibial 
fracture sections were immunostained for p-Smad2. The number of p-Smad2–positive cells 
was quantified as a percentage of the total cells per high power field. n = 5 to 6 mice per 
group. *p < 0.05.
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Fig. 6. 
Hypersecretion of MMP-2/9 promotes excessive latent TGF-β1 activation. (A) Active TGF-
β1, latency associated peptide (LAP)-bound TGF-β1, and β-actin were detected by Western 
blot in protein extracts from the fracture site of Nf1flox/−;Col2.3Cre mice with tibial fracture 
nonunion and WT controls. The bar graph represents the fold change in the active TGF-β1/
LAP-TGF-β1 ratio. n = 5 to 6 mice per group. (B) Activity levels of MMP-2/9 were 
measured in WT and Nf1+/− myeloid cell conditioned medium by zymography. n = 3 
biological replicates. (C) Osteoprogenitors transfected with a Smad luciferase reporter were 
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stimulated with recombinant, active TGF-β1 (1 ng/mL) and latent, LAP-TGF-β1 (100 
ng/mL) for 18 hours. n = 3 technical replicates. The experiment was repeated on two 
independent occasions with similar results. *p < 0.05, **< 0.01. (D) Working model of NF1 
skeletal defects mediated by a pathological cycle of increased TGF-β1 synthesis, activation, 
and Smad signaling.
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